Haemonetics Corporation Common Stock (HAE)

Blood products company Haemonetics (NYSE:HAE) reported calendar Q3 2026 (fiscal Q2 2027) results topping the market’s revenue expectations, with sales up 9.3...

Plasma demand and manufacturing expansion are reshaping the margin outlook.

Blood products company Haemonetics (NYSE:HAE) announced better-than-expected revenue in calendar Q3 2026 (fiscal Q2 2027), with revenue up 9.3% year on year ...

Blood products company Haemonetics (NYSE:HAE) will be reporting earnings this Thursday before market open. Here’s what to expect. Haemonetics beat analysts’ ...

Haemonetics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 96.3%, reaching $118.21 per share. This was partly ...

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

What Happened? Shares of blood products company Haemonetics (NYSE:HAE) jumped 12.4% in the morning session after CSL Plasma announced intentions to complete ...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Haemonetics (NYSE:HAE) and it...

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Shares of Haemonetics Corp (NYSE: HAE) are trading higher Tuesday afternoon following news of a significant commercial agreement.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Plasma disposables surged 25% as Persona PLUS adoption accelerated globally.

Haemonetics delivered a Q2 performance that surpassed Wall Street’s revenue and adjusted earnings expectations, supported by consistent execution across its ...

Haemonetics (NYSE:HAE) reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and aphe